Assembly Biosciences to Present at 2015 RBC Capital Markets Healthcare Conference

.gnw_heading {font: 16px Arial; text-align: center}

.gnw_subhead {font: 12px Arial; text-align: center}

.gnw_colhead {font: 12px Arial; text-align: center}

.gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;}

.gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;}

.gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left }

.gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;}

.gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;}

.gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;}

.gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;}

.gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;}

.gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;}

.gnw_label_ulinetop {font: 12px Arial; vertical-align: bottom; text-align: left; border-top: solid black 1.0pt;}

.gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;}

.gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;}

.gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 15.0px;}

.gnw_label_i20 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 20.0px;}

.gnw_label_i25 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 25.0px;}

.gnw_label_i30 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 30.0px;}

.gnw_num {font: 12px Arial; vertical-align: bottom; text-align: right; white-space: nowrap;}

.gnw_num_uline {font: 12px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; border-bottom: solid black 1.0pt;}

.gnw_num_ulinetop {font: 12px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; border-top: solid black 1.0pt;}

.gnw_num_dline {font: 12px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; border-bottom: double black 2.5pt;}

.gnw_num_dlinetop {font: 12px Arial; vertical-align: bottom; text-align: right; white-space: nowrap; border-top: double black 2.5pt;}

.gnw_data {font: 12px Arial; vertical-align: bottom; text-align: left; white-space: nowrap;}

.gnw_data_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;}

.gnw_data_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;}

.gnw_news_media_box { margin-top: 15px; margin-left: 6px; margin-bottom: 6px; margin-right: 6px; border-width: 1px; border-color: #A9A9A9; border-style: solid; }

.gnw_media_caption { font-size: 8pt; font-family: Verdana, Arial, Helvetica, Geneva, Swiss, SunSans-Regular }

.gnw_media_bgcolor { background-color: transparent }

.gnw_table { border-collapse: separate; border-spacing: 6px }

.gnw_videotitle {font: bold 12px Arial; color: #1d5296;}

.gnw_border_top_solid {border-top: solid black 1px!important;}

.gnw_border_right_solid {border-right: solid black 1px!important;}

.gnw_border_bottom_solid {border-bottom: solid black 1px!important;}

.gnw_border_left_solid {border-left: solid black 1px!important;}

.gnw_border_top_double {border-top: double black 3px!important;}

.gnw_border_right_double {border-right: double black 3px!important;}

.gnw_border_bottom_double {border-bottom: double black 3px!important;}

.gnw_border_left_double {border-left: double black 3px!important;}

.gnw_table_border_collapse {border-collapse: collapse!important;}

.gnw_table_border_collapse td {padding-left: 3px!important; padding-right: 3px!important;}

.gnw_align_left {text-align: left!important;}

.gnw_align_center {text-align: center!important;}

.gnw_align_right {text-align: right!important;}

.gnw_align_justify {text-align: justify!important;}

.gnw_vertical_align_top {vertical-align: top!important;}

.gnw_vertical_align_middle {vertical-align: middle!important;}

.gnw_vertical_align_bottom {vertical-align: bottom!important;}

.gnw_padding_left_none {padding-left: 0 !important;}

.gnw_padding_right_none {padding-right: 0 !important;}

NEW YORK, Feb. 20, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in the 2015 RBC Capital Markets Healthcare Conference at the New York Palace Hotel in New York City. Assembly's Chief Executive Officer Derek Small and Chief Medical Officer Uri Lopatin will present on February 25, 2015 at 4:05pm ET. A breakout session will follow.

The Assembly presentation will be webcast live at: http://www.veracast.com/webcasts/rbc/healthcare2015/15215363045.cfm. The archived webcast will be available starting approximately one hour after the live event and will remain archived at this address for 90 days.

About Assembly Biosciences

Assembly Biosciences, Inc. is a public biopharmaceutical company developing novel oral therapies for the cure of intractable infectious diseases, focusing on hepatitis B virus (HBV) and C. difficile-associated infections (CDAD). Its HBV-Cure research team is discovering and developing multiple core protein allosteric modifiers (CpAMs) with the potential to modulate the HBV core protein—a polyfunctional essential viral protein-—at multiple complementary points in the viral lifecycle. The goal is to eradicate the infection with an orally-administered regimen. Assembly is uniquely positioned to execute on this strategy, with a senior scientific team that has over 30 years of combined experience working on HBV. The company's CDAD program is based on the targeted delivery of novel microbiome-based therapies in a
proprietary oral formulation. Assembly has created a network of world-class microbiome scientists from academia and industry to help advance this innovative program. For more information visit www.assemblybio.com.   

CONTACT: Corporate:

         Assembly Biosciences, Inc.

         David Barrett

         646-706-5208

         dbarrett@assemblybio.com



         Media:

         BLL Partners LLC

         Barbara Lindheim

         212-584-2276

         blindheim@bllbiopartners.com

Source: Assembly Biosciences

News Provided by Acquire Media